Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients

References

• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny, E., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:28–2018. doi:10.1056/NEJMoa1501824
   Web of Science ®Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens, R A., et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:7–2980. doi:10.1200/jco.2016.66.9929
   Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:50–1540. doi:10.1016/s0140-6736(15)01281-7
   Web of Science ®Google Scholar
• Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 2016;11:88–976. doi:10.1016/j.jtho.2016.02.015
   Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:35–123. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med. 2016;13:70–157. doi:10.20892/j.issn.2095-3941.2016.0009
   Web of Science ®Google Scholar
• Kerr Km, Tsao Ms, Nicholson Ag, Yatabe Y, Wistuba, II, Hirsch Fr. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10:9–985. doi:10.1097/jto.0000000000000526
   Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West, A N., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:71–568. doi:10.1038/nature13954
   Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:608–2598. doi:10.1158/1535-7163.mct-17-0386
   Web of Science ®Google Scholar
• Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, Martinez A, Nuciforo P, Comerma L, Alos L, Pardo, N. et al Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 2017;77:50–3540. doi:10.1158/0008-5472.can-16-3556
   Web of Science ®Google Scholar
• Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan, O. et al CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:5–101. doi:10.1038/nature23643
   Web of Science ®Google Scholar
• Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks, A. et al Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:10–106. doi:10.1038/nature23669
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:16–409. doi:10.1093/annonc/mdv615
   PubMed Web of Science ®Google Scholar
• Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber, R D. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5:17–106. doi:10.1158/2326-6066.cir-16-0391
   PubMed Web of Science ®Google Scholar
• Nakamura S, Hayashi K, Imaoka Y, Kitamura Y, Akazawa Y, Tabata K, Groen R, Tsuchiya T, Yamasaki N, Nagayasu T, Fukuoka, J., Deb, S. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS One. 2017;12:e0186192. doi:10.1371/journal.pone.0186192
   PubMed Web of Science ®Google Scholar
• Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, Sun N, Wang HS, Zhang S, Li WJ, Zheng, W., et al Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (review). Asian Pac J Cancer Prev. 2016;17:4–2741
   Google Scholar
• Yuan W, Liu B, Wang X, Li T, Xue H, Mo X, Yang S, Ding S, Han W. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett. 2017;386:77–86. doi:10.1016/j.canlet.2016.11.015
   PubMed Web of Science ®Google Scholar
• Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int. 2017;17:113. doi:10.1186/s12935-017-0485-8
   PubMed Web of Science ®Google Scholar
• Yafune A, Kawai M, Itahashi M, Kimura M, Nakane F, Mitsumori K, Shibutani M. Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model. Toxicol Lett. 2013;222:295–302. doi:10.1016/j.toxlet.2013.08.006
   PubMed Web of Science ®Google Scholar
• Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018;35:43–233. doi:10.1016/j.ebiom.2018.08.012
   Web of Science ®Google Scholar
• Zhu X, Qi G, Li C, Bei C, Tan C, Zhang Y, Shi W, Zeng W, Kong J, Fu Y, Tan, S. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. DNA Cell Biol. 2019;38:7–193. doi:10.1089/dna.2018.4513
   PubMed Web of Science ®Google Scholar
• Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F. CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. Ann Transl Med. 2018;6:54. doi:10.21037/atm.2017.11.26
   PubMed Web of Science ®Google Scholar
• O’Hurley G, Sjostedt E, Rahman A, Li B, Kampf C, Ponten F, Gallagher WM, Lindskog C. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol. 2014;8:98–783. doi:10.1016/j.molonc.2014.03.008
   Web of Science ®Google Scholar
• Aviles-Salas A, Muniz-Hernandez S, Maldonado-Martinez HA, Chanona-Vilchis JG, Ramirez-Tirado LA, HernaNdez-Pedro N, Dorantes-Heredia R, Rui ZMJM, Motola-Kuba D, Arrieta O. Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer. Oncol Lett. 2017;13:20–912. doi:10.3892/ol.2016.5512
   Web of Science ®Google Scholar
• Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:8–876 10.1136/jcp.48.9.876
   Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein, L, et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:47–228. doi:10.1016/j.ejca.2008.10.026
   Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:60–1243. doi:10.1097/jto.0000000000000630
   Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson, I. et al Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• McCarty KS, Jr., Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s–8s
   PubMed Web of Science ®Google Scholar
• Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner, M C. et al PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists. Am J Surg Pathol. 2018;42:9–1384. doi:10.1097/pas.0000000000001105
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg, L. et al An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–16.e11. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar